Campbell & Co Investment Adviser’s Vaxcyte PCVX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-42,859	Closed	-$1.54M	–	1344
2025 Q3	$1.54M	Sell	42,859 -31,407	-42%	-$1.04M	0.12%	262
2025 Q2	$2.41M	Buy	+74,266	New	+$2.43M	0.15%	196
2025 Q1	–	Sell	-4,108	Closed	-$336K	–	1261
2024 Q4	$336K	Sell	4,108 -3,092	-43%	-$307K	0.03%	810
2024 Q3	$823K	Sell	7,200 -16,048	-69%	-$1.45M	0.06%	511
2024 Q2	$1.76M	Buy	23,248 +9,775	+73%	+$665K	0.15%	191
2024 Q1	$920K	Sell	13,473 -13,746	-51%	-$952K	0.08%	435
2023 Q4	$1.71M	Buy	27,219 +877	+3%	+$45.5K	0.15%	182
2023 Q3	$1.34M	Buy	26,342 +5,594	+27%	+$276K	0.16%	179
2023 Q2	$1.04M	Buy	+20,748	New	+$983K	0.18%	139

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Campbell & Co Investment Adviser's PCVX Position: Q4 2025 in Review

Campbell & Co Investment Adviser sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 42,859 shares — an estimated $1.54M sold.

Campbell & Co Investment Adviser first reported a position in PCVX in Q2 2023 and held it in 9 quarters. The position peaked at $2.41M in Q2 2025. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

Campbell & Co Investment Adviser reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
Campbell & Co Investment Adviser sold 42,859 Vaxcyte shares in Q4 2025, an estimated $1.54M.
Campbell & Co Investment Adviser first reported a position in Vaxcyte in Q2 2023 and held it in 9 quarters.
Campbell & Co Investment Adviser's Vaxcyte position peaked at $2.41M in Q2 2025.
295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2025, filed 12 Feb 2026.